MDR-TB TREATMENT UPDATE
Rifampicin-resistant tuberculosis (RR-TB) accounts for an expanding proportion of incident global TB cases and is a major barrier to global tuberculosis control. Conventional therapy for RR-TB is more toxic, less effective, and much more costly than drug-susceptible TB. Treatment success has been co...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | International Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223002503 |